Scott Mendel
About Scott Mendel
Scott Mendel, age 58, joined Quanterix’s Board in July 2025 upon completion of Quanterix’s acquisition of Akoya Biosciences, where he served as Board Chair (Oct 2024–Jul 2025) and director (Jun 2021–Jul 2025) . He brings 30+ years of financial and operating leadership, including CEO/President of GenMark Diagnostics (sold to Roche in Apr 2021), CFO roles at GE Healthcare IT and The Active Network, and an MBA from Northwestern (Kellogg) with a BS in Finance from Indiana University . The Board has determined he is an independent director under Nasdaq standards .
Past Roles
| Organization | Role | Tenure | Committees/Impact |
|---|---|---|---|
| GenMark Diagnostics | President & CEO; President post-acquisition; previously Interim CEO, COO, CFO | CEO May 2020–Apr 2021; President Apr–Sep 2021; various roles 2014–2020 | Led company through sale to F. Hoffmann-La Roche in Apr 2021 |
| The Active Network (SaaS) | Chief Financial Officer | Mar 2010–Dec 2013 | Company was acquired by Vista Equity Partners in Dec 2013 |
| GE Healthcare IT (GE) | Chief Financial Officer; prior finance roles across GE | CFO Mar 2003–Mar 2010; 20+ years at GE | Senior finance leadership in healthcare technology |
External Roles
| Organization | Role | Tenure | Committees/Notes |
|---|---|---|---|
| Quantum-Si (Nasdaq: QSI) | Director | Since May 2023 | Public protein sequencing company |
| Pattern Bioscience (private) | Director | Since May 2024 | Rapid pathogen ID/AST company |
| Akoya Biosciences (acquired) | Director; Chairman | Director Jun 2021–Jul 2025; Chair Oct 2024–Jul 2025 | Joined Quanterix Board at deal close (Jul 8, 2025) |
Board Governance
- Committee assignments (QTRX): As of the 2025 proxy, Mendel is not listed on the Audit, Compensation, or Nominating & Governance Committees. Current committee rosters: Audit—Jeffrey T. Elliott (Chair), William P. Donnelly, Paul M. Meister; Compensation—Karen A. Flynn (Chair), William P. Donnelly, Ivana Magovčević-Liebisch, David R. Walt; Nominating & Governance—Ivana Magovčević-Liebisch (Chair), Jeffrey T. Elliott, Karen A. Flynn .
- Independence: Board designated Mendel independent under Nasdaq standards .
- Attendance: In 2024, all incumbent directors attended at least 75% of Board and committee meetings (Mendel joined in 2025) .
- Tenure: Class I director with term ending at the 2027 Annual Meeting (appointed July 8, 2025) .
- Board leadership and structure: Independent Chair (William P. Donnelly); Board pursuing declassification and adopted majority voting standard for uncontested elections in Aug 2025 per cooperation agreement with Kent Lake .
- Anti-hedging/pledging: Directors and officers are prohibited from hedging or pledging company stock .
Fixed Compensation (Director)
| Component | Amount | Notes |
|---|---|---|
| Annual cash retainer (non-employee director) | $50,000 | Effective Jan 1, 2025 |
| Chair/Lead Director retainer | $95,000 | Effective Jan 1, 2025 |
| Committee fees – Audit | $10,000 member / $20,000 chair | Paid quarterly; directors may elect stock in lieu of cash |
| Committee fees – Compensation | $7,500 member / $15,000 chair | Paid quarterly; stock election available |
| Committee fees – Nominating & Governance | $5,000 member / $10,000 chair | Paid quarterly; stock election available |
Performance Compensation (Director)
| Equity Element | Value/Mix | Vesting | Performance Metrics |
|---|---|---|---|
| Initial equity grant for new directors | $400,000; 60% options / 40% RSUs | Options: 1/3 on 1st anniversary, remainder in 24 equal monthly installments; RSUs: 1/3 annually over 3 years | None; time-based only |
| Annual equity grant | $200,000; 60% options / 40% RSUs | Vests in full on Dec 31 of grant year (for annual awards) | None; time-based only |
Note: The policy provides these terms for all non-employee directors; the 2024 compensation table predates Mendel’s July 2025 appointment .
Other Directorships & Interlocks
- Current public boards: Quantum-Si (QSI) .
- Recent public company leadership: Akoya Biosciences board chair/director until Quanterix acquisition; subsequently appointed to Quanterix Board (potential integration oversight, not a related-party transaction) .
- No related-person transactions involving Mendel were disclosed; related-party items disclosed pertain to director David Walt’s legacy university licenses (royalties to Tufts/Harvard) .
Expertise & Qualifications
- Finance and capital markets expertise (former CFO at GE Healthcare IT; CFO at The Active Network) .
- Diagnostics operating experience and M&A execution (GenMark CEO/President during sale to Roche) .
- Public company governance (service on Quantum-Si board; former Akoya chair) .
- Board skills matrix flags for M&A, capital markets/finance, healthcare industry, public company executive experience (applicable to Mendel) .
Equity Ownership
| Item | Detail |
|---|---|
| Shares beneficially owned (as of 7/31/2025) | 4,189 shares; <1% of outstanding |
| Director stock ownership guideline | 5x annual base cash retainer; 50% of net-after-tax vested shares must be held until met; 5-year attainment window from appointment |
| Hedging/pledging | Prohibited for directors and officers |
Governance Assessment
- Positives: Independent director with deep diagnostics and finance leadership; no disclosed related-party transactions; strong governance framework (independent Chair, anti-hedging/pledging, director stock ownership guidelines) supports alignment and oversight .
- Alignment: Director compensation is equity-heavy and time-vested; new-director initial grant ($400k) and annual grant ($200k) increase long-term alignment; beneficial ownership is modest at appointment but guidelines require build-up over five years .
- Board effectiveness context: 2024 attendance was ≥75% among incumbents; Compensation Committee uses an independent consultant; Say-on-Pay received 98% support in 2024, indicating constructive investor sentiment toward pay governance .
- Watch items: Integration oversight given Mendel’s prior Akoya role (now within Quanterix) and activist engagement resulting in a cooperation agreement (declassification and majority voting) signal active governance change; Mendel currently holds no committee seat—future committee placement (e.g., Audit) could enhance board leverage of his CFO background .